Users of the platform will have access to Kyzatrex.
WellSync is collaborating with Marius Pharmaceuticals to offer a testosterone replacement therapy (TRT) option on the WellSync digital platform.1 Thanks to the partnership, people using the platform will have access to Kyzatrex, an oral TRT treatment approved by FDA.
In a press release, WellSync CEO Clint House said, “Our work with Marius Pharmaceuticals represents a significant step forward in our mission to transform the way healthcare is delivered. By offering Kyzatrex through our virtual care platform, we're delivering a streamlined, accessible, and effective solution for men's health that seamlessly integrates into our clients' existing offerings. Additionally, we're creating a new marketplace for brand manufacturers to leverage our platform to launch their innovative treatments. With the growing demand for health and wellness solutions, particularly in light of the GLP-1 trend, adding this new Kyzatrex low T treatment to our clients' programs perfectly complements our goal of improving access to care while supporting innovative medications that are poised to leverage our direct-to-consumer platform. This collaboration with Marius Pharmaceuticals underscores our commitment to working with leading pharmaceutical companies to bring cutting-edge treatments directly to patients, enhancing their health and well-being."
Marius Pharmaceuticals CEO Shalin Shah added, “At Marius, we prioritize making therapies more accessible to patients. By offering Kyzatrex through WellSync's platform, we're simplifying the process for men to manage their testosterone levels. This effort is an important step toward enhancing healthcare accessibility and improving patient outcomes."
This is just the latest move by WellSync to improve patient access to this particular TRT treatment. Earlier this month, the company announced that it had also partnered with Vitamin Shoppe in order to make Kyzatrex available on its telehealth platform.2
In a press release issued at the time, House said, “WellSync is driving the future of telehealth innovation, transforming the connection between providers and patients by seamlessly modernizing healthcare delivery through the integration of clinical protocols into their online platform. We are thrilled to deepen our partnership with The Vitamin Shoppe by introducing hormone replacement therapy, including Marius Pharmaceuticals' Kyzatrex oral testosterone treatment for men. This new offering reinforces our shared commitment to delivering high-quality, accessible healthcare solutions that greatly enhance consumers' overall health and well-being."
WellSync first announced its general partnership with Vitamin Shoppe in May of this year.3 At the time, House said, “Our partnership with The Vitamin Shoppe is a testament to WellSync's dedication to providing adaptable and seamless virtual health solutions. By leveraging our extensive network of vetted clinician and pharmacy partners, we ensure a reliable supply of GLP-1 medications, even amid potential shortages. This collaboration not only maximizes patient and provider choice but also reinforces our shared mission to offer accessible, personalized care."
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.